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identification of stenotic lesions 50% within the iliac arteries was
sensitivity 86%, specificity 95%, PPV 89%, and NPV 80%. Identifi-
cation of lesions 50% within the femoral arteries was sensitivity
86%, specificity 100%, PPV 100%, and NPV 94%. Identification of
lesions 50% within the superficial femoral arteries was sensitivity
90%, specificity 90%, PPV 90%, and NPV 84%. Hemodynamically
significant lesions (50%) within the popliteal arteries were detected
at sensitivity 90%, specificity 96%, PPV 82%, and NPV 98% via
64-slice peripheral CT.
With improved spatial resolution, decreased slice thickness, and
reduced acquisition times, 64-slice CT angiography has the ability
to detect significant atherosclerotic lesions of the peripheral vas-
culature, while maintaining the ability to reliably identify the
absence of significant arterial blockage. Previous citations suggest
that CT angiography is a valuable diagnostic tool, capable of
accurately ruling out the presence of significant lesions based on
sufficient specificity and negative predictive values (4,5). Previous
limitations of CT angiography were the marginal ability to
sufficiently detect significant lesions and positively predict disease
at a high accuracy level (4). Our results suggest that the 64-slice
generation of multislice CT has sufficient sensitivity and positive
predictive value to allow peripheral CT angiography to be consid-
ered for routine diagnostic evaluations. The agreement between
64-slice peripheral CT and catheter angiography supports the
strength of the latest generation of CT imaging.
The 64-slice peripheral CT angiography findings compare
favorably with traditional catheterization in this study of patients
assessed for PAD. The prospect of utilizing peripheral CT
angiography in lieu of catheter angiography is appealing based
upon the patient-friendly, non-invasive nature of the procedure, as
well as the markedly reduced economic impact of CT angiography
when compared to catheterization. Among the carotid, renal, and
lower extremity arteries both sensitivity and specificity were suffi-
ciently high to rely upon results of peripheral CT angiography
when evaluating the presence of PAD.
Our analysis suggests that 64-slice peripheral CT angiography is an
accurate and reliable method of non-invasively assessing PAD. The
noninvasive nature of this diagnostic test allows for PAD detection
that is time efficient for both the patient and medical care providers.
Collectively, these advantages of 64-slice peripheral CT angiogra-
phy may enhance its use as a PAD diagnostic tool.
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Letters to the Editor
Serum Plant Sterols and
Atherosclerosis: Is There a Place
for Statin-Ezetimibe Combination?
We read with interest the paper by Miettinen et al. (1) demonstrating that
the higher the absorption of cholesterol, the higher the plant sterol
contents are in serum resulting in their higher contents in atherosclerotic
plaque. The prospective Cardiovascular Münster (PROCAM) study
found that people in the upper quartile of sitosterol levels had a 1.8-fold
increased risk of major coronary events compared with those in the lower
three quartiles (2). Statin treatment decreases cholesterol synthesis but
increases absorption of plant sterols (3). In the Scandinavian Simvastatin
Survival Study (4S), no reduction was observed in recurrence of coronary
heart disease with the use of simvastatin in patients with high baseline
plant sterol contents and with marked increase of serum plant sterols
during the five-year treatment period (4). Additional treatment with
inhibition of sterol absorption (e.g., with plant stanol esters) was suggested
for this particular group of patients (3,4). To this respect, we were
surprised that Miettinen et al. (1) did not consider the potential of
combining ezetimibe with statin. Indeed, in addition to inhibiting
intestinal cholesterol absorption, a well-known effect, ezetimibe also
reduces plasma concentrations of the non-cholesterol sterols sitosterol and
campesterol, suggesting an effect on the absorption of these compounds as
well (5). It has been demonstrated recently that the Niemann-Pick
Table 1. Accuracy Data by Peripheral Region
Peripheral Vessels n Sensitivity Specificity PPV NPV
Renal arteries 119 92% 92% 88% 92%
Carotid arteries 88 96% 100% 100% 95%
Total lower extremities 770 88% 96% 91% 90%
Iliac arteries 203 86% 95% 89% 80%
Femoral arteries 182 85% 100% 100% 94%
Superficial femoral arteries 193 90% 90% 90% 84%
Popliteal arteries 192 90% 96% 82% 98%
NPV  negative predictive value; PPV  positive predictive value.
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C1-like 1 (NPC1L1) transporter is most likely responsible for the
transport of cholesterol and plant sterols from the brush border mem-
brane into the intestinal mucosa (6). The intestinal absorption of plant
sterols differs markedly from that of cholesterol and their biliary excretion
as well. The presence of two specific ABCG5/ABCG8 transporters in
the intestinal wall is responsible for rapid resecretion of plant sterols into
the intestine lumen and thus rather low intestinal absorption of campes-
terol and sitosterol, and their presence in the liver explains why plant
sterols are excreted much faster in the bile than cholesterol (7,8).
Ezetimibe interferes with NPC1L1, reducing the intestinal uptake of
cholesterol and plant sterols (6–8). Interestingly, the reduction of plant
sterol serum levels with ezetimibe was significantly more pronounced
than the reduction of serum cholesterol (7,8). Clinical data on ezetimibe
could demonstrate that the concept of inhibiting intestinal absorption of
neutral sterols is beneficial in both patients with hypercholesterolemia as
well in patients with hypersitosterolemia, an inherited disease with
identified mutations in ABCG5/ABCG8 transporters that leads to a
high prevalence of cardiovascular disease (9). Recent observations, such as
those by Miettinen et al. (1), that elevated serum plant sterols pose an
increased cardiovascular risk suggest that increases of serum plant sterol
levels should be avoided, especially in atherosclerosis-prone individuals
(1). Therefore, subjects with high cholesterol absorption and low synthe-
sis may need a therapy combining statin and ezetimibe to lower more
effectively their serum cholesterol levels and prevent an increase in the
levels of plant sterols (3). The question remains, however, as to whether
lowering serum levels of plant sterols (especially in high-absorber patients
on statin therapy) with a drug such as ezetimibe will decrease the
incidence of coronary artery disease.
*Régis P. Radermecker, MD
André J. Scheen, MD, PhD
*Division of Diabetes, Nutrition, and Metabolic Disorders
Department of Medicine
CHU Liège
University of Liège
B-4000 Liège
Belgium
E-mail: regis.radermecker@ulg.ac.be
doi:10.1016/j.jacc.2006.01.031
REFERENCES
1. Miettinen TA, Railo M, Lepäntalo M, Gylling H. Plant sterols in
serum and in atherosclerotic plaques of patients undergoing carotid
endarterectomy. J Am Coll Cardiol 2005;45:1794–801.
2. Assmann G, Cullen P, Erbey JR, et al. Elevation in plasma sitosterol
concentration is associated with an increased risk for coronary events in
the PROCAM study (abstr). Circulation 2003;108:IV730.
3. Miettinen TA, Strandberg TE, Gylling H, for the Finnish Investigators
of the Scandinavian Simvastatin Survival Study Group. Noncholesterol
sterols and cholesterol lowering by long-term simvastatin treatment in
coronary patients. Relation to basal serum cholesterol. Arterioscler
Thromb Vasc Biol 2000;20:1340–6.
4. Miettinen TA, Gylling H, Strandberg T, Sarna S, for the Finnish 4S
Investigators. Baseline serum cholestanol as predictor of recurrent
coronary events in subgroup of Scandinavian simvastatin survival study.
BMJ 1998;316:1127–30.
5. Sudhop T, Lütjohann D, Kodal A, et al. Inhibition of intestinal
cholesterol absorption by ezetimibe in humans. Circulation 2002;106:
1943–8.
6. Davis HR, Zhu LJ, Hoos LM, et al. Niemann-Pick C1 Like 1
(NPC1L1) is the intestinal phytosterol and cholesterol transporter and
a key modulator of whole body cholesterol homeostasis. J Biol Chem
2004;279:33586–92.
7. von Bergmann K, Sudhop T, Lütjohann D. Cholesterol and plant sterol
absorption: recent insights. Am J Cardiol 2005;96 Suppl:10D–4D.
8. Sudhop T, Lütjohann D, von Bergmann K. Sterol transporters: targets
of natural sterols and new lipid lowering drugs. Pharmacol Ther
2005;105:333–41.
9. Salen G, von Bergmann K, Lütjohann D, et al. Ezetimibe effectively
reduces plasma plant sterols in patients with sitosterolemia. Circulation
2004;109:966–71.
REPLY
In the letter by Drs. Radermecker and Scheen, it was noted that we
have not commented the potential of combining ezetimibe to
statins (1). The additional low-density lipoprotein (LDL) lowering
of combining cholesterol absorption inhibitors to statins is rela-
tively small, usually approximately 15%, for instance, for ezetimibe
or plant stanols. No clinical studies have been published defining
their additional reduction of coronary events during these treat-
ments, which seems to be true also for their monotherapy, even
though they are suitable for treatment of modestly increased LDL
cholesterol, and stanol ester management also provides the heart-
healthy fatty acids. Relatively low LDL cholesterol lowering either in
mono- or in combination with statin treatment certainly requires
randomized large-enough study populations treated for relatively long
periods of time to record changes in heart events. In addition to
LDL cholesterol lowering, cholesterol absorption inhibitors lower
also plant sterol levels off or on statin treatment. Thus, they also
normalize statin-induced increase of plant sterols. The endarter-
ectomized patients treated with statin in our study had increased
serum plant sterol ratios to cholesterol, which appeared also to be
reflected in atheromatous plaques of carotid arteries (1). This
finding certainly rises a question as to whether the lowering of
serum plant sterols with cholesterol absorption inhibitors, e.g.,
ezetimibe or plant stanols, also could reduce plant sterol contents
in the plaques. However, it also raises the question of whether an
increase of serum plant sterols, e.g., during the consumption of
plant sterol-enriched functional foods, also could enhance their
concentrations in atheromatous plaques. Several studies have
shown that increased serum plant sterols, even their ratios to
cholesterol, are associated with enhanced coronary artery disease in
crossover or follow-up investigations (2). However, in the Scan-
dinavian Simvastatin Survival Study, no association was found in
the control group between the five-year coronary events and
baseline plant sterol concentrations or ratios to cholesterol (2). In
the respective simvastatin treatment group, coronary events were
reduced significantly in the low absorber but unchanged in the
high absorbers, suggesting that additional lowering of LDL
cholesterol is needed in the latter type of patients, e.g., by
combination with cholesterol malabsorption. Statin treatment
seems to improve endothelial function of carotid arteries despite
increasing serum plant sterols (3); however, vascular function was
unaffected with phytosterol-enriched food when LDL cholesterol
was lowered and serum plant sterols were increased (4,5). Drs.
Radermecker and Scheen concluded that “elevated serum plant
sterols pose an increased cardiovascular risk,” but clinical heart
event reduction with their pharmacological lowering is still open.
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